ImmuneXcite's Series C Round

ImmuneXcite raised a round of funding on December 10, 2015.

ImmuneXcite has developed a platform technology for enhancing the efficacy of therapeutic monoclonal antibodies for oncological and infectious disease targets.…

Articles about ImmuneXcite's Series C Round: